LLY · News · 20260806N

Guidance and Outlook

ELI LILLY & Co · 2026-08-06 · Importance 75 · Surprise 60

Lilly raised its full-year 2026 revenue guidance to $85.0 billion-$87.0 billion after second-quarter revenue exceeded analyst expectations. The outlook increase reflects continued demand and volume growth for Mounjaro and Zepbound despite pricing pressure. Management also cited Foundayo adoption, retatrutide development and expanded manufacturing capacity as future growth drivers.

Key facts

• Multiple outlets noted management cited volume gains despite price declines as a driver for raised 2026 revenue guidance to $85–87 billion. source